Avacta Appoints New R&D Chief For Affimer Antibodies Alternative London South East Avacta acquired the intellectual property rights to Affimer - an alternative to the antibodies widely used in life-sciences research, diagnostics and therapeutics - in February 2012. In July of this year the company raised GBP4.7 million in a share ... Avacta appoints expert to lead technology development team Avacta names head of R&D |
